Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Direct-Acting Antiviral Treatment May Reduce Mortality in Patients With HCC History

Publish date:: November 12, 2019

Key clinical point: For patients with a complete response following treatment for hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC), treatment with direct-acting antiviral therapy was linked to significantly reduced mortality compared with no such treatment.

Major finding: Treatment with DAA therapy was associated with improved overall survival, according to results of multivariable analysis, with a hazard ratio of 0.54 (95% confidence interval, 0.33-0.90).

Study details: Multicenter, retrospective North American cohort study of 797 patients with HCV-related HCC who achieved complete response following treatment.

Disclosures: Dr. Singal reported disclosures related to AbbVie, Bayer, BMS, Eisai, Exact Sciences, Exelixis, Genentech, Gilead FOCUS, Glycotest, GRAIL, Merck, Roche, TARGET Pharmasolutions, and Wako Diagnostics.

Citation:

Singal AG et al. The Liver Meeting 2019, Abstract 199.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,